06 September 2024
The human papillomavirus (HPV) vaccine is set to be included in Russia’s National Immunization Schedule by 2026, according to Elena Uvarova, the Chief Pediatric and Adolescent Gynecologist at the Russian Ministry of Health. “Currently, the HPV vaccine is not part of the national schedule, but a tentative date has been set for 2026 to include it alongside other vaccines in the National Immunization Schedule,” Uvarova announced at a press conference on Friday. She also noted that a domestically produced, quadrivalent HPV vaccine is currently under development in Russia.
“Research is underway as part of the initial stages of vaccine production, and clinical trials are already in progress. We hope that by 2026, the vaccine will be ready for widespread use,” Uvarova added. In March 2024, it was reported that Nanolek received approval from the Russian Ministry of Health to conduct the third phase of clinical trials for the HPV vaccine. These trials will involve 402 children and adolescents aged 9 to 17 years.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025
Russia Begins Production of Terbium-161 Isotope for Cancer Therapy
10 January 2025
FMBA has begun clinical trials of a vaccine against five serotypes of meningococcus
10 January 2025